This animal study demonstrates that GHRP-6 (related to Annular’s Growth-1295) significantly improved heart function and reduced tissue damage after heart attack by enhancing mitochondrial metabolism and reducing inflammation. The research provides strong preclinical evidence for cardioprotective benefits of growth hormone-releasing peptides. This supports the therapeutic potential of Annular’s Growth-1295 for cardiovascular applications in clinical practice.
For your business
New research shows growth hormone-releasing peptides like our Growth-1295 demonstrate significant cardioprotective effects, improving heart function and reducing tissue damage after cardiac events.